β3-receptor agonists for overactive bladder - New frontier or more of the same?

Current Urology Reports

Volumn 14, Issue 5, 2013, Pages 435-441

  Andersson, Karl Erik ^a,b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b WAKE FOREST BAPTIST HEALTH   (United States)

Author keywords

Adverse effect profile; Antimuscarinics; Clinical efficacy; Mechanisms of action; Mirabegron

Indexed keywords

5 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL] 1,3 BENZODIOXOLE 2,2 DICARBOXYLIC ACID; BETA 3 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; DARIFENACIN; FESOTERODINE; FLAVOXATE; MIRABEGRON; MOXIFLOXACIN; MUSCARINIC RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; PLACEBO; PROPIVERINE; SOLIFENACIN; TOLTERODINE; TROSPIUM CHLORIDE;

ABDOMINAL PAIN; ACCOMMODATION PARALYSIS; ARTHRALGIA; ARTICLE; BLADDER CAPACITY; BLADDER CONTRACTION; BLADDER DISTENSION; BLOOD BRAIN BARRIER; BLURRED VISION; CARDIOTOXICITY; CARDIOVASCULAR EFFECT; COMBINATION CHEMOTHERAPY; CONSTIPATION; DIARRHEA; DRUG ABSORPTION; DRUG APPROVAL; DRUG CHOICE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FATIGUE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART RATE; HUMAN; HYPERTENSION; LIPOPHILICITY; MOLECULAR SIZE; MONOTHERAPY; MULTIPLE DRUG DOSE; NAUSEA; NONHUMAN; OUTCOME ASSESSMENT; OVERACTIVE BLADDER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POLYMORPHIC VENTRICULAR TACHYCARDIA; PULSE RATE; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR UPREGULATION; RHINOPHARYNGITIS; SIDE EFFECT; TACHYCARDIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TORSADE DES POINTES; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URGE INCONTINENCE; URINARY TRACT INFECTION; XEROSTOMIA;

ACETANILIDES; ADRENERGIC BETA-3 RECEPTOR AGONISTS; HUMANS; MUSCARINIC ANTAGONISTS; PRACTICE GUIDELINES AS TOPIC; THIAZOLES; URINARY BLADDER; URINARY BLADDER, OVERACTIVE; URINATION;

EID: 84886782472     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-013-0335-8     Document Type: Article

References (53)

1. Gormley EA, Lightner DJ, Burgio KL, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults:AUA/SUFU guideline. American Urological Association; Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction. J Urol. 2012;188(6 Suppl):2455-63.
2. Lucas MG, Bosch RJ, Burkhard FC, et al. EAU guidelines on assessment and nonsurgical management of urinary incontinence. Eur Urol. 2012;62(6):1130-42.
3. Chapple CR, Khullar V, Gabriel Z, et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol. 2008;54(3):543-62.
4. Novara G, Galfano A, Secco S, et al. Systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder. Eur Urol. 2008;54(4):740-63.
5. •• Andersson KE, Chapple CR, Cardozo L, et al. Pharmacological treatment of urinary incontinence. In: Incontinence. ed by AbramsP, Cardozo L, Khoury A, Wein A. 5th International Consultation on Incontinence, Paris February 2012, ICUD-EAU 2013:625-728. Up-to-date review of current treatments.
6. Andersson KE, Martin N, Nitti V. Selective β3-Adrenoceptor Agonists in the Treatment of the Overactive Bladder. J Urol. 2013b Feb 28. [Epub ahead of print]
7. Ursino MG, Vasina V, Raschi E, Crema F, De Ponti F. The beta3-adrenoceptor as a therapeutic target: current perspectives. Pharmacol Res. 2009;59(4):221-34.
8. Andersson KE. Muscarinic acetylcholine receptors in the urinary tract. Handb Exp Pharmacol. 2011;202:319-44.
9. Abrams P, Andersson KE. Muscarinic receptor antagonists for overactive bladder. BJU Int. 2007;100(5):987-1006.
10. Andersson KE. Antimuscarinic mechanisms and the overactive detrusor: an update. Eur Urol. 2011;59(3):377-86.
11. Roosen A, Chapple CR, Dmochowski RR, et al. A refocus on the bladder as the originator of storage lower urinary tract symptoms: a systematic review of the latest literature. Eur Urol. 2009;56(5):810-9.
12. Hood B, Andersson KE. Common theme for drugs effective in overactive bladder treatment: Inhibition of afferent signaling from the bladder. Int J Urol. 2013;20(1):21-7.
13. Gillespie JI. The autonomous bladder: a view of the origin of bladder overactivity and sensory urge. BJU Int. 2004;93(4):478-83.
14. Kanai A, Andersson KE. Bladder afferent signaling: recent findings. J Urol. 2010;183(4):1288-95.
15. Birder L, Andersson KE. Urothelial signaling. Physiol Rev. 2013;93(2):653-80.
16. Iggo A. Tension receptors in the stomach and the urinary bladder. J Physiol. 1955;128(3):593-607.
17. Biers SM, Reynard JM, Brading AF. The effects of a new selective beta3-adrenoceptor agonist (GW427353) on spontaneous activity and detrusor relaxation in human bladder. BJU Int. 2006;98(6):1310-4.
18. Takasu T, Ukai M, Sato S, et al. Effect of (R)-2-(2-aminothiazol-4-yl)- 4'-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function. J Pharmacol Exp Ther. 2007;321(2):642-7.
19. Svalø J, Nordling J, Bouchelouche K, et al. The novel β(3)-adrenoceptor agonist mirabegron reduces carbachol-induced contractile activity in detrusor tissue from patients with bladder outflow obstruction with or without detrusor overactivity. Eur J Pharmacol. 2012;699(1-3):101-5.
20. Hatanaka T, Ukai M, Watanabe M, et al. In vitro and in vivo pharmacological profile of the selective β(3)-adrenoceptor agonistmirabegron in rats. Naunyn Schmiedebergs Arch Pharmacol. 2012 Dec 14. [Epub ahead of print]
21. Hatanaka T, Ukai M, Watanabe M, et al. Effect of mirabegron, a novel β(3)-adrenoceptor agonist, on bladder function during storage phase in rats. Naunyn Schmiedebergs Arch Pharmacol. 2013;386(1):71-8.
22. Gillespie JI, Palea S, Guilloteau V, et al. Modulation of non-voiding activity by the muscarinergic antagonist tolterodine and the β(3)-adrenoceptor agonist mirabegron in conscious rats with partial outflow obstruction. BJU Int. 2012;110(2 Pt 2):E132-42.
23. Aizawa N, Igawa Y, Nishizawa O, Wyndaele JJ. Effects of CL316,243, a β3 adrenoreceptor agonist, and intravesical prostaglandin E2 on the primary bladder afferent activity of the rat. Neurourol Urodyn. 2010;29:771-6.
24. • Aizawa N, Homma Y, Igawa Y. Effects of mirabegron, a novel β3-adrenoceptor agonist, on primary bladder afferent activity and bladder microcontractions in rats compared with the effects of oxybutynin. Eur Urol. 2012;62(6):1165-73. Nice demonstration of mirabegron effects on bladder Aδ - and C-fiber afferents.
25. Guay DR. Clinical pharmacokinetics of drugs used to treat urge incontinence. Clin Pharmacokinet. 2003;42(14):1243-85.
26. Andersson KE, Fullhase C, Soler R. Urothelial effects of oral agents for overactive bladder. Curr Urol Rep. 2008;9(6):459-64.
27. Eltink C, Lee J, Schaddelee M, et al. Single dose pharmacokinetics and absolute bioavailibility of mirabegron, a β3-adrenoceptor agonist for treatment of overactive bladder. Int J Clin Pharmacol Ther. 2012;50(11):838-50.
28. Krauwinkel W, van Dijk J, Schaddelee M, et al. Pharmacokinetic Properties of Mirabegron, a β(3)-Adrenoceptor Agonist: Results From Two Phase I, Randomized, Multiple-Dose Studies in Healthy Young and Elderly Men and Women. Clin Ther. 2012;34(10):2144.
29. Füllhase C, Soler R, Westerling-Andersson K, Andersson KE. Beta3-adrenoceptors in the rat sacral spinal cord and their functional relevance in micturition under normal conditions and in a model of partial urethral obstruction. Neurourol Urodyn. 2011;30(7):1382-7.
30. Takusagawa S, van Lier JJ, Suzuki K, et al. Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers. Drug Metab Dispos. 2012;40(4):815.
31. Takusagawa S, Yajima K, Miyashita A, et al. Identification of human cytochrome P450 isoforms and esterases involved in the metabolism of mirabegron, a potent and selective β(3)-adrenoceptor agonist. Xenobiotica. 2012 Apr 18. [Epub ahead of print]
32. Takusagawa S, Miyashita A, Iwatsubo T, Usui T. In vitro inhibition and induction of human cytochrome P450 enzymes by mirabegron, a potent and selective β3-adrenoceptor agonist. Xenobiotica. 2012 Jul 27. [Epub ahead of print]
33. Basra RK, Wagg A, Chapple C, Cardozo L, Castro-Diaz D, et al. A review of adherence to drug therapy in patients with overactive bladder. BJU Int. 2008;102(7):774-9.
34. Sears CL, Lewis C, Noel K, Albright TS, Fischer JR. Overactive bladder medication adherence when medication is free to patients. J Urol. 2010;183:1077-81.
35. Wagg A, Compion G, Fahey A, Siddiqui E. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. BJU Int. 2012;110(11):1767-74.
36. Gomes T, Juurlink DN, Mamdani MM. Comparative adherence to oxybutynin or tolterodine among older patients. Eur J Clin Pharmacol. 2012;68(1):97-9.
37. Lee YS, Choo MS, Lee JY, Oh SJ, Lee KS. Symptom change after discontinuation of successful antimuscarinic treatment in patients with overactive bladder symptoms: a randomised, multicentre trial. Int J Clin Pract. 2011;65(9):997-1004.
38. •• Uvin P, Boudes M, Franken J, et al. Why anticholinergics fail: Oxybutynin and fesoterodine induce a shift from muscarinergic to purinergic transmission in the rat bladder. Eur Urol Suppl. 2013;12:e441. Interesting preliminary report suggestion tolerance development to muscarinic receptor blockade.
39. Chapple CR, Dvorak V, Radziszewski P, et al. On behalf of the Dragon Investigator Group. A phase II dose-ranging study of mirabegron in patients with overactive bladder. Int Urogynecol J. 2013 Mar 8. [Epub ahead of print]
40. Chapple CR, Dvorak V, Radziszewski P, et al. On behalf of the Dragon Investigator Group. A proof-of-concept study: Mirabegron, a new therapy for overactive bladder. Neurourol Urodyn. 2013 Feb 19. [Epub ahead of print]
41. Nitti VW, Auerbach S, Martin N, et al. Results of a Randomized Phase III Trial of Mirabegron in Patients with Overactive Bladder. J Urol. 2013;189(4):1388-95.
42. Khullar V, Amarenco G, Angulo JC, et al. Efficacy and Tolerability of Mirabegron, a β(3)-Adrenoceptor Agonist, in Patients with Overactive Bladder: Results from a Randomised European-Australian Phase 3 Trial. Eur Urol. 2013;63(2):283-95.
43. Van Kerrebroeck P, Barkin Z, Castro-Diaz D, et al. Randomised, double-blind, placebo-controlled Phase III study to assess the efficacy and safety of mirabegron 25 mg and 50 mg once daily in overactive bladder (OAB). Beijing: Presented at the International Continence Society Meeting; 2012.
44. •• Chapple CR, Kaplan SA, Mitcheson D, et al. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder. Eur Urol. 2013;63(2):296-305. The first long-term study of mirabegron with a toterodine treatment arm.
45. Madhuvrata P, Cody JD, Ellis G, et al. Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst Rev. 2012;18:1. CD005429.
46. Kessler TM, Bachmann LM, Minder C, et al. Adverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approach. PLoS One. 2011;6(2):e16718.
47. Andersson KE, Olshansky B. Treating patients with overactive bladder syndrome with antimuscarinics: heart rate considerations. BJU Int. 2007;100(5):1007-14.
48. Andersson KE, Campeau L, Olshansky B. Cardiac effects of muscarinic receptor antagonists used for voiding dysfunction. Br J Clin Pharm. 2011;72:186-96.
49. Nitti V, Rosenberg S, Mitcheson HD, et al. Randomized, multicenter phase II study evaluating the urodynamic safety of mirabegron in males with lower urinary tract symptoms (LUTS) and bladder outlet. J Urol. 2012;187(4 suppl):e756.
50. Mirabegron prescribing information. http://www.us.astellas.com/docs/ myrbetriq-full-pi.pdf. Accessed 1 May 2013.
51. • Malik M, van Gelderen EM, Lee JH, et al. Proarrhythmic Safety of Repeat Doses of Mirabegron in Healthy Subjects: A Randomized, Double-Blind, Placebo-, and Active-Controlled Thorough QT Study. Clin Pharmacol Ther. 2012;92(6):696. Important documentation of cardiac effects of mirabegron.
52. 3-adrenoceptor agonists on contractions induced by electrical field stimulation of rat isolated urinary bladder strips. Eur Urol Suppl. 2013;12:e440.
53. Abrams P, Kelleher C, Staskin D, et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder (OAB) - Efficacy results from a phase 2 study (Symphony). J Urol Suppl. 2013;189(4S):e803.